AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31321875 — intervention group
Group type: COMPARATOR
Intervention: Control group (no transporter inhibitor)
Number of subjects: 288
Study 31322059 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline placental growth factor concentrations in incident T2DM cases
Number of subjects: 1052
Study 31322059 — intervention group
Group type: COMPARATOR
Intervention: Reference subcohort
Number of subjects: 1052
Study 31322652 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese individuals with higher cardiorespiratory fitness
Number of subjects: 138
Study 31322652 — intervention group
Group type: COMPARATOR
Intervention: Normal weight individuals
Number of subjects: 138
Study 31322672 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise Training (ET)
Number of subjects: 70
Study 31322672 — intervention group
Group type: COMPARATOR
Intervention: RYGB only (Control)
Number of subjects: 70
Study 31322702 — intervention group
Group type: EXPERIMENTAL
Intervention: BYL719 (phosphatidylinositol-3-kinase α inhibitor)
Number of subjects: 0
Study 31322702 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (mammalian target of rapamycin inhibitor)
Number of subjects: 0
Study 31322702 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of BYL719 and Everolimus
Number of subjects: 0
Study 31322702 — intervention group
Group type: EXPERIMENTAL
Intervention: BYL719 alone or in combination with Everolimus
Number of subjects: 0
Study 31322702 — intervention group
Group type: EXPERIMENTAL
Intervention: BYL719 plus Everolimus in human pheochromocytoma primary cultures
Number of subjects: 0
Study 31323045 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine (active medication)
Number of subjects: 41
Study 31323045 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 41
Study 31323075 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir (DTG)
Number of subjects: 3
Study 31323075 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz (EFV)
Number of subjects: 3
Study 31323075 — intervention group
Group type: COMPARATOR
Intervention: Raltegravir (RAL)
Number of subjects: 3
Study 31323075 — intervention group
Group type: COMPARATOR
Intervention: Darunavir/Ritonavir (DRV/r)
Number of subjects: 3
Study 31323705 — intervention group
Group type: EXPERIMENTAL
Intervention: REP 2139-Ca therapy
Number of subjects: 12
Study 31323705 — intervention group
Group type: COMPARATOR
Intervention: Untreated matched controls
Number of subjects: 12
Study 31324189 — intervention group
Group type: EXPERIMENTAL
Intervention: rs2076295 in the DSP gene
Number of subjects: 4685
Study 31324189 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung function based polygenic risk score
Number of subjects: 4685
Study 31324256 — intervention group
Group type: EXPERIMENTAL
Intervention: ReWalk exoskeleton training
Number of subjects: 11
Study 31324600 — intervention group
Group type: EXPERIMENTAL
Intervention: Obinutuzumab 1000 mg intravenous infusions over six 4-weekly cycles and ibrutinib 420 mg oral once per day for 9 months
Number of subjects: 135
Study 31324600 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib 420 mg oral once per day for 6 additional months (for patients with complete response and minimal residual disease <0.01%)
Number of subjects: 135
Study 31324600 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib 420 mg oral once per day plus fludarabine, cyclophosphamide, and obinutuzumab 1000 mg for 6 months (for patients with partial response or complete response with minimal residual disease ≥0.01%)
Number of subjects: 135
Study 31324600 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events during treatment
Number of subjects: 135
Study 31324679 — intervention group
Group type: EXPERIMENTAL
Intervention: Frailty (defined by GFI ≥4)
Number of subjects: 696
Study 31324679 — intervention group
Group type: COMPARATOR
Intervention: Prefracture health status (HS)
Number of subjects: 696
Study 31325010 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic pyloromyotomy
Number of subjects: 0
Study 31325020 — intervention group
Group type: EXPERIMENTAL
Intervention: Positional therapy (PT)
Number of subjects: 292
Study 31325020 — intervention group
Group type: COMPARATOR
Intervention: Continuous positive airway pressure (CPAP)
Number of subjects: 292
Study 31325044 — intervention group
Group type: EXPERIMENTAL
Intervention: hsTnT undetectable (<5 ng/L)
Number of subjects: 280
Study 31325044 — intervention group
Group type: EXPERIMENTAL
Intervention: hsTnT normal (5-14 ng/L)
Number of subjects: 280
Study 31325044 — intervention group
Group type: EXPERIMENTAL
Intervention: hsTnT stable elevated (15-51 ng/L)
Number of subjects: 280
Study 31325044 — intervention group
Group type: EXPERIMENTAL
Intervention: hsTnT >99th percentile
Number of subjects: 280
Study 31325044 — intervention group
Group type: COMPARATOR
Intervention: Dual antiplatelet therapy (DAPT)
Number of subjects: 280
Study 31325044 — intervention group
Group type: COMPARATOR
Intervention: Coronary angiography (CA)
Number of subjects: 280
Study 31325044 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 280
Study 31325044 — intervention group
Group type: EXPERIMENTAL
Intervention: Significant obstructive coronary artery disease requiring PCI
Number of subjects: 280
Study 31325105 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus plus exemestane
Number of subjects: 27
Study 31326088 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 102
Study 31326088 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 102
Study 31326088 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 102
Study 31326088 — intervention group
Group type: COMPARATOR
Intervention: Drug-independent system
Number of subjects: 102
Study 31326397 — intervention group
Group type: COMPARATOR
Intervention: CDK4
Number of subjects: 260
Study 31326397 — intervention group
Group type: COMPARATOR
Intervention: CDKN2A
Number of subjects: 260
Study 31326957 — intervention group
Group type: EXPERIMENTAL
Intervention: Waterpipe tobacco (WPT) smoking session with 10 g of WPT and 470 mL of water
Number of subjects: 50
Study 31326957 — intervention group
Group type: EXPERIMENTAL
Intervention: Waterpipe device cleaning practices
Number of subjects: 50
Study 31326957 — intervention group
Group type: EXPERIMENTAL
Intervention: Disposal practices for smoked WPT residue
Number of subjects: 50
Study 31326957 — intervention group
Group type: EXPERIMENTAL
Intervention: Disposal practices for postsmoking charcoal
Number of subjects: 50
Study 31326957 — intervention group
Group type: EXPERIMENTAL
Intervention: Disposal practices for smoked WP water
Number of subjects: 50
Study 31327453 — intervention group
Group type: EXPERIMENTAL
Intervention: Watchful Waiting
Number of subjects: 0
Study 31327618 — intervention group
Group type: EXPERIMENTAL
Intervention: MBEVAR for TAAAs and PRAAs in patients with prior aortic dissections
Number of subjects: 162
Study 31327618 — intervention group
Group type: COMPARATOR
Intervention: MBEVAR for TAAAs and PRAAs in patients without prior aortic dissections
Number of subjects: 162
Study 31328895 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternate-Day Fasting (ADF)
Number of subjects: 43
Study 31328895 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily Calorie Restriction (CR)
Number of subjects: 43
Study 31328895 — intervention group
Group type: COMPARATOR
Intervention: Control regimen
Number of subjects: 43
Study 31329313 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab + peanut oral immunotherapy (pOIT)
Number of subjects: 23
Study 31329510 — intervention group
Group type: EXPERIMENTAL
Intervention: MoistureMeterD Compact Device
Number of subjects: 0
Study 31329510 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitting Test
Number of subjects: 0
Study 31329854 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual global long-axis strain (LAS) assessment
Number of subjects: 1235
Study 31329922 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim 3.6 mg administered at least 24 h after cabazitaxel infusion
Number of subjects: 21
Study 31329922 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabazitaxel 25 mg/m2 every 3 weeks, up to 10 cycles, with oral prednisolone 10 mg daily
Number of subjects: 21
Study 31329922 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 21
Study 31330239 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar Disorder (BD)
Number of subjects: 118
Study 31330239 — intervention group
Group type: EXPERIMENTAL
Intervention: Disruptive Mood Dysregulation Disorder (DMDD)
Number of subjects: 118
Study 31330239 — intervention group
Group type: COMPARATOR
Intervention: Healthy Volunteers (HV)
Number of subjects: 118
Study 31330239 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar Disorder (BD) and Disruptive Mood Dysregulation Disorder (DMDD)
Number of subjects: 118
Study 31330556 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 G fine-needle aspiration (FNA) followed by 20 G fine-needle biopsy (FNB)
Number of subjects: 73
Study 31330556 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 G fine-needle biopsy (FNB) followed by 25 G fine-needle aspiration (FNA)
Number of subjects: 73
Study 31331295 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaratumab (60 mg/kg twice weekly) + mouse anti-PDGFRA antibody 1E10 (20 mg/kg twice weekly)
Number of subjects: 4
Study 31331295 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin (3 mg/kg once weekly)
Number of subjects: 4
Study 31331295 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of doxorubicin and anti-PDGFRA
Number of subjects: 4
Study 31331295 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 4
Study 31331342 — intervention group
Group type: EXPERIMENTAL
Intervention: TNF blockade
Number of subjects: 45
Study 31331342 — intervention group
Group type: COMPARATOR
Intervention: Non-TNF blockade
Number of subjects: 45
Study 31331342 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 45
Study 31331370 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant Folfox Cetuximab after complete cytoreductive surgery (CCS)
Number of subjects: 12
Study 31331393 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational and nutritional interventions
Number of subjects: 0
Study 31331393 — intervention group
Group type: EXPERIMENTAL
Intervention: Duodenal biopsies
Number of subjects: 0
Study 31331393 — intervention group
Group type: EXPERIMENTAL
Intervention: RNA-Seq
Number of subjects: 0
Study 31331393 — intervention group
Group type: EXPERIMENTAL
Intervention: Omic analyses
Number of subjects: 0
Study 31331393 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioinformatic tools
Number of subjects: 0
Study 31331399 — intervention group
Group type: EXPERIMENTAL
Intervention: Guadecitabine
Number of subjects: 128
Study 31331591 — intervention group
Group type: EXPERIMENTAL
Intervention: Truncal regional anaesthesia (TRA)
Number of subjects: 122
Study 31331591 — intervention group
Group type: COMPARATOR
Intervention: No block (Control)
Number of subjects: 122
Study 31331701 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib (800 mg/day) continuously until disease progression or unacceptable toxicity
Number of subjects: 26
Study 31331701 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib (800 mg/day)
Number of subjects: 26
Study 31331917 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib 560 mg once daily, lenalidomide, and rituximab
Number of subjects: 0
Study 31331918 — intervention group
Group type: EXPERIMENTAL
Intervention: ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) for patients achieving complete response (CR) on PET scan after cycle 2 (PET2)
Number of subjects: 331
Study 31331918 — intervention group
Group type: EXPERIMENTAL
Intervention: eBEACOPP (escalated bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) for patients not achieving CR on PET2
Number of subjects: 331
Study 31331918 — intervention group
Group type: COMPARATOR
Intervention: ABVD
Number of subjects: 331
Study 31331918 — intervention group
Group type: COMPARATOR
Intervention: eBEACOPP
Number of subjects: 331
Study 31331918 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 331
Study 31331994 — intervention group
Group type: EXPERIMENTAL
Intervention: Duodenal mucosal resurfacing (DMR)
Number of subjects: 46
Study 31332032 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin Dose
Number of subjects: 0
Study 31332032 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 31332046 — intervention group
Group type: EXPERIMENTAL
Intervention: Tisagenlecleucel
Number of subjects: 7
Study 31332062 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine pharmacokinetics (PK) evaluated during anti-TB therapy
Number of subjects: 53
Study 31332062 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine pharmacokinetics (PK) evaluated after completing anti-TB therapy
Number of subjects: 53
Study 31332068 — intervention group
Group type: EXPERIMENTAL
Intervention: WCK 4282 (Cefepime-Tazobactam Combination)
Number of subjects: 48
Study 31332649 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose 12/400-µg Formoterol/Budesonide combination
Number of subjects: 33
Study 31333075 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary cardiomyopathy patients
Number of subjects: 60
Study 31333075 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic variants of interest
Number of subjects: 60
Study 31333075 — intervention group
Group type: EXPERIMENTAL
Intervention: Late gadolinium enhancement
Number of subjects: 60
Study 31333456 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese Herbal Medicine combined with EGFR-TKI
Number of subjects: 0
Study 31333456 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31333489 — intervention group
Group type: COMPARATOR
Intervention: Healthy Sedentary (HS)
Number of subjects: 140
Study 31333489 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Active (HA)
Number of subjects: 140
Study 31333489 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary Patients with Increased CV Risk (SR)
Number of subjects: 140
Study 31333511 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan as an add-on therapy to Methylphenidate
Number of subjects: 0
Study 31333511 — intervention group
Group type: COMPARATOR
Intervention: Methylphenidate
Number of subjects: 0
Study 31334125 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Diclofenac
Number of subjects: 0
Study 31334298 — intervention group
Group type: EXPERIMENTAL
Intervention: Preemptive switch to efavirenz (EFV)
Number of subjects: 2
Study 31334298 — intervention group
Group type: EXPERIMENTAL
Intervention: LPV/r with second-line option
Number of subjects: 2
Study 31334298 — intervention group
Group type: COMPARATOR
Intervention: Continued LPV/r
Number of subjects: 2
Study 31334480 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer counseling combined with psychosocial stimulation (PC + PCS)
Number of subjects: 350
Study 31334480 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 350
Study 31334546 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant follicle-stimulating hormone (FSH) stimulation with a flexible antagonist protocol
Number of subjects: 22
Study 31334596 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab 10 mg/kg every 3 weeks
Number of subjects: 688
Study 31334596 — intervention group
Group type: COMPARATOR
Intervention: Ipilimumab 3 mg/kg every 3 weeks
Number of subjects: 688
Study 31334596 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixture TGD model-based measures of tumor response
Number of subjects: 688
Study 31334635 — intervention group
Group type: EXPERIMENTAL
Intervention: AB680, a potent human CD73 inhibitor
Number of subjects: 0
Study 31334704 — intervention group
Group type: EXPERIMENTAL
Intervention: One-month dual antiplatelet therapy (DAPT)
Number of subjects: 858
Study 31334762 — intervention group
Group type: COMPARATOR
Intervention: Low latent height class (LHC) in boys
Number of subjects: 536
Study 31334762 — intervention group
Group type: COMPARATOR
Intervention: High latent height class (LHC) in boys
Number of subjects: 536
Study 31334925 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical collagen powder
Number of subjects: 8
Study 31334925 — intervention group
Group type: COMPARATOR
Intervention: Primary closure
Number of subjects: 8
Study 31335117 — intervention group
Group type: EXPERIMENTAL
Intervention: NIR photoimmunotherapy (NIR-PIT) using IRdye700DX conjugated with a monoclonal antibody targeting cancer cell surface antigens.
Number of subjects: 0
Study 31335117 — intervention group
Group type: EXPERIMENTAL
Intervention: NIR photoimmunotherapy (NIR-PIT)
Number of subjects: 0
Study 31335283 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary CT angiography with fractional flow reserve analysis
Number of subjects: 0
Study 31335283 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 31335321 — intervention group
Group type: EXPERIMENTAL
Intervention: CAR-T therapy
Number of subjects: 56
Study 31335321 — intervention group
Group type: COMPARATOR
Intervention: ASCT
Number of subjects: 56
Study 31335773 — intervention group
Group type: EXPERIMENTAL
Intervention: Perfluorobutane Microsphere-Enhanced Ultrasound
Number of subjects: 0
Study 31336587 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutrophil-to-Lymphocyte Ratio (NLR) in delirious patients
Number of subjects: 1001
Study 31336587 — intervention group
Group type: EXPERIMENTAL
Intervention: Early-onset delirium incidence
Number of subjects: 1001
Study 31337344 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluad® (adjuvanted inactivated trivalent influenza vaccine)
Number of subjects: 200
Study 31337344 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluad®
Number of subjects: 200
Study 31337428 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG-PET/CT
Number of subjects: 24
Study 31337428 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG-PET/MRI
Number of subjects: 24
Study 31337428 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 24
Study 31338061 — intervention group
Group type: EXPERIMENTAL
Intervention: TARGET® Intracranial Aneurysm Coiling
Number of subjects: 0
Study 31338476 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabilone (0.5-2 mg)
Number of subjects: 0
Study 31338476 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31338480 — intervention group
Group type: EXPERIMENTAL
Intervention: Classroom Communication Resource (CCR)
Number of subjects: 454
Study 31338480 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 454
Study 31338660 — intervention group
Group type: COMPARATOR
Intervention: Controlled group (CGE-DC: controlled)
Number of subjects: 228
Study 31338660 — intervention group
Group type: COMPARATOR
Intervention: Not-controlled group (CGE-DC: not controlled)
Number of subjects: 228
Study 31338660 — intervention group
Group type: COMPARATOR
Intervention: Treatment-naïve patients
Number of subjects: 228
Study 31338660 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall disease control evaluation
Number of subjects: 228
Study 31338800 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole 15 mg every 12 hours (q12h) for 5 days
Number of subjects: 70
Study 31338800 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole 30 mg every 12 hours (q12h) for 5 days
Number of subjects: 70
Study 31338800 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole 30 mg every 12 hours (q12h) for 5 days
Number of subjects: 70
Study 31339003 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous CT-guided cryovagotomy
Number of subjects: 20
Study 31340773 — intervention group
Group type: EXPERIMENTAL
Intervention: High baseline Tie1 levels
Number of subjects: 65
Study 31340773 — intervention group
Group type: EXPERIMENTAL
Intervention: High baseline Tie1 and Ang2 levels
Number of subjects: 65
Study 31340773 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline Ang2 levels
Number of subjects: 65
Study 31340825 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation
Number of subjects: 92
Study 31340825 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation responders
Number of subjects: 92
Study 31340870 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quintile of total dietary fibre intake (compared to lowest quintile)
Number of subjects: 35380
Study 31340868 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual microcirculation parameters in septic patients
Number of subjects: 40
Study 31340868 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro AFM data
Number of subjects: 40
Study 31340872 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-satiety phenotype (LSP)
Number of subjects: 96
Study 31340872 — intervention group
Group type: COMPARATOR
Intervention: High-satiety phenotype (HSP)
Number of subjects: 96
Study 31340872 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-satiety phenotype (LSP) under high energy-density (HED) conditions
Number of subjects: 96
Study 31340965 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary dual marker strategy (DMS) discharge group
Number of subjects: 2294
Study 31340965 — intervention group
Group type: COMPARATOR
Intervention: Conventional workup group
Number of subjects: 2294
Study 31340982 — intervention group
Group type: EXPERIMENTAL
Intervention: Zanubrutinib 160 mg twice daily
Number of subjects: 144
Study 31340982 — intervention group
Group type: COMPARATOR
Intervention: Zanubrutinib 320 mg once daily
Number of subjects: 144
Study 31340982 — intervention group
Group type: EXPERIMENTAL
Intervention: Zanubrutinib (various doses: 40, 80, 160, or 320 mg once daily or 160 mg twice daily)
Number of subjects: 144
Study 31340982 — intervention group
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Number of subjects: 144
Study 31341158 — intervention group
Group type: EXPERIMENTAL
Intervention: Test cohort (n=98)
Number of subjects: 329
Study 31341158 — intervention group
Group type: EXPERIMENTAL
Intervention: Replication cohort (n=131)
Number of subjects: 329
Study 31341158 — intervention group
Group type: COMPARATOR
Intervention: Diagnostic biomarker based on GM volume pattern
Number of subjects: 329
Study 31341158 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (n=66)
Number of subjects: 329
Study 31341663 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 31342318 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive decline on personalized test selection
Number of subjects: 25